Literature DB >> 28008206

Aggressive resection of frequent peritoneal recurrences in colorectal cancer contributes to long-term survival.

Koji Komori1, Takashi Kinoshita1, Oshiro Taihei1, Seiji Ito1, Tetsuya Abe1, Yoshiki Senda1, Kazunari Misawa1, Yuich Ito1, Norihisa Uemura1, Seiji Natsume1, Jiro Kawakami1, Akira Ouchi1, Masayuki Tsutsuyama1, Takahiro Hosoi1, Itaru Shigeyoshi1, Tomoyuki Akazawa1, Daisuke Hayashi1, Hideharu Tanaka1, Yasuhiro Shimizu1.   

Abstract

We report a long-term survivor of colorectal cancer who underwent aggressive, frequent resection for peritoneal recurrences. A 58-year-old woman was diagnosed with descending colon cancer. Resection of the descending colon along with lymph node dissection was performed in September 2006. The pathological findings revealed Stage IIA colorectal cancer. The following peritoneal recurrences were removed: two in July 2007, two in the omental fat and two in the pouch of Douglas in June 2008 resected by low anterior resection of the rectum, one in the uterus and right ovarian recurrence resected via bilateral adnexectomy and Hartmann's procedure in May 2011, and one in the ascending colon by partial resection of the colon wall in December 2011. Postoperative adjuvant chemotherapy (uracil and tegafur/leucovorin, fluorouracil/levofolinate/oxaliplatin/bevacizumab, 5-fluorouracil/leucovorin/bevacizumab, irinotecan/bevacizumab, and irinotecan/panitumumab) was administered. The patient did not desire postoperative adjuvant chemotherapy after the fourth operation. The long-term survival was 6 years and 7 months.

Entities:  

Keywords:  aggressive resection; colorectal cancer; frequent peritoneal recurrences

Year:  2016        PMID: 28008206      PMCID: PMC5159476          DOI: 10.18999/nagjms.78.4.501

Source DB:  PubMed          Journal:  Nagoya J Med Sci        ISSN: 0027-7622            Impact factor:   1.131


  8 in total

1.  Cytoreductive surgery and perioperative intraperitoneal chemotherapy in patients with peritoneal carcinomatosis of colonic origin: outcomes after 7 years' experience of a new centre for peritoneal surface malignancies.

Authors:  Pedro Bretcha-Boix; Jose Farré-Alegre; Manuel Sureda; Carlos Dussan; Juan José Pérez Ruixo; Antonio Brugarolas Masllorens
Journal:  Clin Transl Oncol       Date:  2010-06       Impact factor: 3.405

2.  Prognostic factors for peritoneal carcinomatosis originating from colorectal cancer: an analysis of 921 patients from a multi-institutional database.

Authors:  Heita Ozawa; Kenjiro Kotake; Hirotoshi Kobayashi; Hirotoshi Kobayashi; Kenichi Sugihara
Journal:  Surg Today       Date:  2014-09       Impact factor: 2.549

3.  Randomised phase III trial of adjuvant chemotherapy with oral uracil and tegafur plus leucovorin versus intravenous fluorouracil and levofolinate in patients with stage III colorectal cancer who have undergone Japanese D2/D3 lymph node dissection: final results of JCOG0205.

Authors:  Yasuhiro Shimada; Tetsuya Hamaguchi; Junki Mizusawa; Norio Saito; Yukihide Kanemitsu; Nobuhiro Takiguchi; Masayuki Ohue; Takeshi Kato; Yasumasa Takii; Toshihiko Sato; Naohiro Tomita; Shigeki Yamaguchi; Makoto Akaike; Hideyuki Mishima; Yoshiro Kubo; Kenichi Nakamura; Haruhiko Fukuda; Yoshihiro Moriya
Journal:  Eur J Cancer       Date:  2014-06-20       Impact factor: 9.162

4.  Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) delivered via a modified perfusion system for peritoneal carcinomatosis of colorectal origin.

Authors:  Adrian Cravioto-Villanueva; Magdalena Cavazos; Pedro Luna-Perez; Hector Martinez-Gomez; María Lourdes Ramirez; Juan Solorzano; Hermelindo Montiel; Jesus Esquivel
Journal:  Surg Today       Date:  2016-04-30       Impact factor: 2.549

5.  [A case report of advanced mucinous adenocarcinoma of the transverse colon with peritoneal dissemination effectively treated by multidisciplinary approach with a focus on FOLFOX4 therapy combined with panitumumab].

Authors:  Tomonari Asano; Masataka Negita; Takanori Uemura; Daishi Takagi; Masashi Hattori; Isao Kamiya
Journal:  Gan To Kagaku Ryoho       Date:  2012-07

6.  Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial.

Authors:  Yasuhide Yamada; Daisuke Takahari; Hiroshi Matsumoto; Hideo Baba; Masato Nakamura; Kazuhiro Yoshida; Motoki Yoshida; Shigeyoshi Iwamoto; Ken Shimada; Yoshito Komatsu; Yasutsuna Sasaki; Taroh Satoh; Keiichi Takahashi; Hideyuki Mishima; Kei Muro; Masahiko Watanabe; Yuh Sakata; Satoshi Morita; Yasuhiro Shimada; Kenichi Sugihara
Journal:  Lancet Oncol       Date:  2013-11-11       Impact factor: 41.316

7.  Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2014 for treatment of colorectal cancer.

Authors:  Toshiaki Watanabe; Michio Itabashi; Yasuhiro Shimada; Shinji Tanaka; Yoshinori Ito; Yoichi Ajioka; Tetsuya Hamaguchi; Ichinosuke Hyodo; Masahiro Igarashi; Hideyuki Ishida; Soichiro Ishihara; Megumi Ishiguro; Yukihide Kanemitsu; Norihiro Kokudo; Kei Muro; Atsushi Ochiai; Masahiko Oguchi; Yasuo Ohkura; Yutaka Saito; Yoshiharu Sakai; Hideki Ueno; Takayuki Yoshino; Narikazu Boku; Takahiro Fujimori; Nobuo Koinuma; Takayuki Morita; Genichi Nishimura; Yuh Sakata; Keiichi Takahashi; Osamu Tsuruta; Toshiharu Yamaguchi; Masahiro Yoshida; Naohiko Yamaguchi; Kenjiro Kotake; Kenichi Sugihara
Journal:  Int J Clin Oncol       Date:  2015-03-18       Impact factor: 3.402

8.  A phase II clinical study of mFOLFOX6 plus bevacizumab as first-line therapy for Japanese advanced/recurrent colorectal cancer patients.

Authors:  Tomohiro Nishina; Yoshinao Takano; Tadamichi Denda; Hisateru Yasui; Koji Takeda; Takashi Ura; Taito Esaki; Yusuke Okuyama; Ken Kondo; Yasuo Takahashi; Yasuyuki Sugiyama; Kei Muro
Journal:  Jpn J Clin Oncol       Date:  2013-09-01       Impact factor: 3.019

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.